An update on chemotherapy for osteosarcoma

Stefano Ferrari, Massimo Serra

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Introduction: In the early seventies chemotherapy significantly improved survival in osteosarcoma. Since then minor innovations have occurred although recent years have offered insights of clinical and scientific relevance.Areas covered: This review focuses on the most recent results of phase 3 and 2 studies. Published data or presentations at International meetings are discussed. A specific section discusses recent insights from studies supporting the hypothesis of a possible personalized chemotherapy approach.Expert opinion: Osteosarcoma is a rare tumor and any effort should be made to improve the level of International collaboration. The MAP (methotrexate, doxorubicin and cisplatin) regimen has become the treatment of choice. Poor pathological response to primary chemotherapy is confirmed as a predictive factor of survival and, presently with the available drugs, it is not recommended to intensify or change post-operative treatment on the basis of pathological response to primary chemotherapy. The genomic complexity and the heterogeneity of osteosarcoma makes active and effective molecularly targeted therapies unlikely to be available in the near future. A relation between pharmacogenetic profile and chemotherapy toxicity and prognosis has been reported. The new frontier for clinical research in osteosarcoma is to optimize the use of the active drugs available by personalizing chemotherapy treatment.

Original languageEnglish
Pages (from-to)2727-2736
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number18
DOIs
Publication statusPublished - Dec 12 2015

Fingerprint

Osteosarcoma
Drug Therapy
Pharmacogenetics
Expert Testimony
Therapeutics
Methotrexate
Pharmaceutical Preparations
Doxorubicin
Cisplatin
Research
Neoplasms

Keywords

  • cisplatin
  • doxorubicin
  • ifosfamide
  • methotrexate
  • mifamurtide
  • neoadjuvant chemotherapy
  • osteosarcoma
  • pharmacogenetics
  • prognostic factors
  • salvage chemotherapy
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

An update on chemotherapy for osteosarcoma. / Ferrari, Stefano; Serra, Massimo.

In: Expert Opinion on Pharmacotherapy, Vol. 16, No. 18, 12.12.2015, p. 2727-2736.

Research output: Contribution to journalArticle

Ferrari, Stefano ; Serra, Massimo. / An update on chemotherapy for osteosarcoma. In: Expert Opinion on Pharmacotherapy. 2015 ; Vol. 16, No. 18. pp. 2727-2736.
@article{079d468bf23343d19567ebb32acd5e18,
title = "An update on chemotherapy for osteosarcoma",
abstract = "Introduction: In the early seventies chemotherapy significantly improved survival in osteosarcoma. Since then minor innovations have occurred although recent years have offered insights of clinical and scientific relevance.Areas covered: This review focuses on the most recent results of phase 3 and 2 studies. Published data or presentations at International meetings are discussed. A specific section discusses recent insights from studies supporting the hypothesis of a possible personalized chemotherapy approach.Expert opinion: Osteosarcoma is a rare tumor and any effort should be made to improve the level of International collaboration. The MAP (methotrexate, doxorubicin and cisplatin) regimen has become the treatment of choice. Poor pathological response to primary chemotherapy is confirmed as a predictive factor of survival and, presently with the available drugs, it is not recommended to intensify or change post-operative treatment on the basis of pathological response to primary chemotherapy. The genomic complexity and the heterogeneity of osteosarcoma makes active and effective molecularly targeted therapies unlikely to be available in the near future. A relation between pharmacogenetic profile and chemotherapy toxicity and prognosis has been reported. The new frontier for clinical research in osteosarcoma is to optimize the use of the active drugs available by personalizing chemotherapy treatment.",
keywords = "cisplatin, doxorubicin, ifosfamide, methotrexate, mifamurtide, neoadjuvant chemotherapy, osteosarcoma, pharmacogenetics, prognostic factors, salvage chemotherapy, tyrosine kinase inhibitors",
author = "Stefano Ferrari and Massimo Serra",
year = "2015",
month = "12",
day = "12",
doi = "10.1517/14656566.2015.1102226",
language = "English",
volume = "16",
pages = "2727--2736",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "18",

}

TY - JOUR

T1 - An update on chemotherapy for osteosarcoma

AU - Ferrari, Stefano

AU - Serra, Massimo

PY - 2015/12/12

Y1 - 2015/12/12

N2 - Introduction: In the early seventies chemotherapy significantly improved survival in osteosarcoma. Since then minor innovations have occurred although recent years have offered insights of clinical and scientific relevance.Areas covered: This review focuses on the most recent results of phase 3 and 2 studies. Published data or presentations at International meetings are discussed. A specific section discusses recent insights from studies supporting the hypothesis of a possible personalized chemotherapy approach.Expert opinion: Osteosarcoma is a rare tumor and any effort should be made to improve the level of International collaboration. The MAP (methotrexate, doxorubicin and cisplatin) regimen has become the treatment of choice. Poor pathological response to primary chemotherapy is confirmed as a predictive factor of survival and, presently with the available drugs, it is not recommended to intensify or change post-operative treatment on the basis of pathological response to primary chemotherapy. The genomic complexity and the heterogeneity of osteosarcoma makes active and effective molecularly targeted therapies unlikely to be available in the near future. A relation between pharmacogenetic profile and chemotherapy toxicity and prognosis has been reported. The new frontier for clinical research in osteosarcoma is to optimize the use of the active drugs available by personalizing chemotherapy treatment.

AB - Introduction: In the early seventies chemotherapy significantly improved survival in osteosarcoma. Since then minor innovations have occurred although recent years have offered insights of clinical and scientific relevance.Areas covered: This review focuses on the most recent results of phase 3 and 2 studies. Published data or presentations at International meetings are discussed. A specific section discusses recent insights from studies supporting the hypothesis of a possible personalized chemotherapy approach.Expert opinion: Osteosarcoma is a rare tumor and any effort should be made to improve the level of International collaboration. The MAP (methotrexate, doxorubicin and cisplatin) regimen has become the treatment of choice. Poor pathological response to primary chemotherapy is confirmed as a predictive factor of survival and, presently with the available drugs, it is not recommended to intensify or change post-operative treatment on the basis of pathological response to primary chemotherapy. The genomic complexity and the heterogeneity of osteosarcoma makes active and effective molecularly targeted therapies unlikely to be available in the near future. A relation between pharmacogenetic profile and chemotherapy toxicity and prognosis has been reported. The new frontier for clinical research in osteosarcoma is to optimize the use of the active drugs available by personalizing chemotherapy treatment.

KW - cisplatin

KW - doxorubicin

KW - ifosfamide

KW - methotrexate

KW - mifamurtide

KW - neoadjuvant chemotherapy

KW - osteosarcoma

KW - pharmacogenetics

KW - prognostic factors

KW - salvage chemotherapy

KW - tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84952720396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952720396&partnerID=8YFLogxK

U2 - 10.1517/14656566.2015.1102226

DO - 10.1517/14656566.2015.1102226

M3 - Article

C2 - 26512909

AN - SCOPUS:84952720396

VL - 16

SP - 2727

EP - 2736

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 18

ER -